IBDEI2C6 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37322,0)
 ;;=E11.59^^146^1915^18
 ;;^UTILITY(U,$J,358.3,37322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37322,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Compl NEC
 ;;^UTILITY(U,$J,358.3,37322,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,37322,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,37323,0)
 ;;=E11.610^^146^1915^27
 ;;^UTILITY(U,$J,358.3,37323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37323,1,3,0)
 ;;=3^DM Type 2 w/ Diab Neuropath Arthropathy
 ;;^UTILITY(U,$J,358.3,37323,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,37323,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,37324,0)
 ;;=E11.618^^146^1915^22
 ;;^UTILITY(U,$J,358.3,37324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37324,1,3,0)
 ;;=3^DM Type 2 w/ Diab Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,37324,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,37324,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,37325,0)
 ;;=E11.620^^146^1915^24
 ;;^UTILITY(U,$J,358.3,37325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37325,1,3,0)
 ;;=3^DM Type 2 w/ Diab Dermatitis
 ;;^UTILITY(U,$J,358.3,37325,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,37325,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,37326,0)
 ;;=E11.622^^146^1915^34
 ;;^UTILITY(U,$J,358.3,37326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37326,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,37326,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,37326,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,37327,0)
 ;;=E11.628^^146^1915^33
 ;;^UTILITY(U,$J,358.3,37327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37327,1,3,0)
 ;;=3^DM Type 2 w/ Skin Compl NEC
 ;;^UTILITY(U,$J,358.3,37327,1,4,0)
 ;;=4^E11.628
 ;;^UTILITY(U,$J,358.3,37327,2)
 ;;=^5002658
 ;;^UTILITY(U,$J,358.3,37328,0)
 ;;=E11.69^^146^1915^19
 ;;^UTILITY(U,$J,358.3,37328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37328,1,3,0)
 ;;=3^DM Type 2 w/ Complications NEC
 ;;^UTILITY(U,$J,358.3,37328,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,37328,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,37329,0)
 ;;=E11.8^^146^1915^20
 ;;^UTILITY(U,$J,358.3,37329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37329,1,3,0)
 ;;=3^DM Type 2 w/ Complications,Unspec
 ;;^UTILITY(U,$J,358.3,37329,1,4,0)
 ;;=4^E11.8
 ;;^UTILITY(U,$J,358.3,37329,2)
 ;;=^5002665
 ;;^UTILITY(U,$J,358.3,37330,0)
 ;;=E10.51^^146^1915^13
 ;;^UTILITY(U,$J,358.3,37330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37330,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,37330,1,4,0)
 ;;=4^E10.51
 ;;^UTILITY(U,$J,358.3,37330,2)
 ;;=^5002610
 ;;^UTILITY(U,$J,358.3,37331,0)
 ;;=E10.52^^146^1915^12
 ;;^UTILITY(U,$J,358.3,37331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37331,1,3,0)
 ;;=3^DM Type 1 w/ Diab Periph Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,37331,1,4,0)
 ;;=4^E10.52
 ;;^UTILITY(U,$J,358.3,37331,2)
 ;;=^5002611
 ;;^UTILITY(U,$J,358.3,37332,0)
 ;;=E10.59^^146^1915^1
 ;;^UTILITY(U,$J,358.3,37332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37332,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Compl NEC
 ;;^UTILITY(U,$J,358.3,37332,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,37332,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,37333,0)
 ;;=E10.610^^146^1915^10
 ;;^UTILITY(U,$J,358.3,37333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37333,1,3,0)
 ;;=3^DM Type 1 w/ Diab Neuropathy Arthropathy
 ;;^UTILITY(U,$J,358.3,37333,1,4,0)
 ;;=4^E10.610
 ;;^UTILITY(U,$J,358.3,37333,2)
 ;;=^5002613
